News

Natco Pharma Limited submitted a certificate to the BSE Ltd and National Stock Exchange of India Ltd under Regulation 74(5) of the SEBI (Depositories and Participants) Regulations, 2018, for the quarter ended September 30, 2026, confirming that securities received for dematerialization have been mutilated and cancelled and the details of securities were furnished to the stock exchanges, with Venture Capital and Corporate Investments Private Limited acting as the authorized signatory.

Natco Pharma Limited informed the BSE Limited and National Stock Exchange of India Ltd. that the trading window for its securities will be closed for directors, designated persons, and connected individuals from October 1, 2026, until 48 hours after the declaration of the company’s unaudited financial results for the quarter ending September 30, 2026.

Natco Pharma Limited has fixed October 1, 2026, as the record date for a rights issue of equity shares, according to a filing with the Bombay Stock Exchange and National Stock Exchange of India on September 25, 2026.

Natco Pharma Limited announced that its board of directors approved a rights issue of 1,70,58,082 equity shares at a price of Rs 750 per share, totaling Rs 12,79,35,61,500, to eligible shareholders as of the record date of October 1, 2026, with a rights entitlement ratio of 2 shares for every 21 shares held. The rights issue period will run from October 12, 2026, to October 22, 2026, and the company`s outstanding equity shares will increase from 17,91,09,870 to 19,61,67,952 following full subscription.

Natco Pharma Limited will hold a board meeting on September 25, 2026, to finalize details of a rights issue approved on September 9, 2026, which seeks to raise up to Rs 1,300 crore through the issuance of equity shares with a face value of Rs 2 each.